m-mansuri_370x250px

Sanofi’s head of strategy and business development to retire amid company review

pharmafile | November 25, 2019 | News story | Sales and Marketing Bristol Meyers, Gilead, Sanofi, Shell 

One of Sanofi’s most senior strategy bosses is set to retire at the end of the month. Muzammil Mansuri, Executive Vice President of Strategy and Business Development, leaves the company during a strategic review.

Mansuri started out as a research scientist at Shell before moving to Bristol-Meyers. His last role before joining Sanofi in 2016 was the Senior VP of R&D Strategy and Corporate Development at Gilead Sciences.

A spokesperson told Endpoints News that Mansuri had played a key role in Sanofi’s strategic moves over the last four years, overseeing acquisitions and ‘’structuring partnerships and alliances that contributed to the deployment of our strategy and growth’’.  Sanofi said that his retirement was planned.

It is the first management shakeup under new CEO Paul Hudson, who took over on 1 September. Under his leadership the company is carrying out a strategic review due to setbacks experienced under his predecessor. He inherited a company with an R&D department that lags behind the competition, a diabetes arm that is in decline and a slipping stock price. Hudson is expected to unveil the company’s plans for the future at an investor day on 10 December in Cambridge Massachusetts.

Conor Kavanagh

Related Content

Fulcrum Therapeutics and Sanofi enter collaboration for facioscapulohumeral muscular dystrophy treatment

Fulcrum Therapeutics has announced that it has entered into a collaboration and license agreement with …

Sanofi adds €1bn funding for biomanufacturing projects in France

Sanofi has announced that it has made a new investment of at least €1bn for …

Vaccine image

Sanofi and Novavex sign exclusive $1.2bn licensing agreement to co-commercialise COVID-19 vaccine and develop flu-COVID-19 vaccines

French pharma and healthcare company Sanofi and US biotech Novavex, have entered into a co-exclusive …

Latest content